Skip to main content

PCAS: 2021 ANNUAL RESULTS

      Ecully, February, 24, 2022

2021 ANNUAL RESULTS

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated results as of December 31, 2021.

   2020 2021  
in millions of euros     
        
Net sales 194.1 187.0  
        
EBITDA (*) 10.7 -4.6  
 EBITDA margin 5.5% -2.5%  
        
Current operating income (*) -10.8 -28.2  
 Current operating income margin -5.5% -15.1%  
        
Other operating income and expenses -0.2 -0.4  
        
Operating income -11.0 -28.6  
        
Financial result -1.6 -2.9  
Taxes -2.4 -9.0  
        
Net result -14.9 -40.5  
(*) of which research tax credit (CIR): 4.3 M€ in 2020 and 4.1 M€ in 2021      
Audit procedures have been performed and auditor’s report is in progress of being issued.  


Results

The PCAS Group has generated consolidated net sales of €187.0 million as of December 31, 2021, a 3.7% decrease compared to the same period during the previous financial year (-2.6% at a constant exchange rate).

The Pharmaceutical Synthesis business generated sales of €119.6 million, a 11.5% decrease compared to 2020 (a 10.5% decrease at a constant exchange rate). The strong decrease in sales of hydro-alcoholic solutions, compared to peak consumption in 2020, as well as lower volumes on several other products, notably from the Limay site, could not be compensated as initially expected by the increase in Estetrol volumes due to the difficulties faced in the production of this molecule manufactured on behalf of Mithra at the new highly active pharmaceutical drug production workshop located in Villeneuve-La-Garenne.

Net sales of Fine Specialty Chemicals totaled €67.4 million, a 14.4% increase compared to 2020 (+15.7% at a constant exchange rate). All activities experienced strong growth in their sales, notably with a very strong demand in Electronics and Lubricants, and strong recovery in Cosmetics. Supply and logistics difficulties have been closely monitored and had therefore a limited impact on sales. Demand for new projects continues to show a good dynamic.

The delay in Estetrol sales, as well as a level of revenue that is still broadly insufficient to cover the additional fixed costs incurred at several production plants in recent years in order to improve the quality of manufacturing processes, are the main reasons explaining an EBITDA of -€4,6 million, compared to €10,7 million in 2020, representing a margin of -2.5% vs. 5.5% in 2020. The resulting current operating income was also sharply down at -€28.6 million, compared to -€11.0 million in 2020.

The financial result showed a loss of €2.9 million in 2021, compared to a €1.6 million loss in 2020.

In 2021 the corporate income tax expense included an expense of €6.3m due to the cancellation of deferred tax assets on tax loss carryforwards, due to a lower profit forecast for the years to come for the Group’s French entities.

The PCAS Group’s net result was a loss of €40.5 million in 2021, compared to a loss of €14.9 million in 2020.

The Group’s net debt (including net current account credit balance with Seqens) totaled €172.7 million vs. €133.4 million at December 31, 2020.

Outlook

The whole PCAS Group team, with the support of its shareholder Seqens for the financing of its activities and its development, are fully mobilized for a return to positive results in 2023.


NEXT FINANCIAL DISCLOSURE:

2021 Shareholder’s Meeting, May 24, 2022

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With about 11% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €187.0 million in 2021 and employs nearly 1200 people in six countries.

To find out more about PCAS: www.pcas.com

PCASNewCap

Pierre Luzeau / Eric Moissenot

Emmanuel Huynh / Louis-Victor Delouvrier
Financial communication and investor relation

Tel.: +33 1 69 79 60 00
www.pcas.com
Tel.: +33 1 44 71 98 53
pcas@newcap.eu
  

 

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.